AKT1 and type 2 diabetes mellitus: Moderately inducing the PI3K-Akt signaling pathway in pancreatic β cells has, in fact, been suggested as a therapeutic strategy to preserve β cell mass during the development of type 1 and type 2 diabetes [42].